The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

V.a

Pleural effusion (uni- or bilateral) (can accompany DI-LDs)

Publications

Lambard J, Vincent J, Roge JM, Akoun G, Michel PL

[Pleuro-pulmonary fibrosis caused by methysergide].

La Nouvelle presse medicale. 1981;10(29):2440-1

Gefter WB, Epstein DM, Bonavita JA, Miller WT

Pleural thickening caused by Sansert and Ergotrate in the treatment of migraine.

AJR. American journal of roentgenology. 1980;135(2):375-7

Hindle W, Posner E, Sweetnam MT, Tan RS

Pleural effusion and fibrosis during treatment with methysergide.

British medical journal. 1970;1(5696):605-6

Dunn JM, Sloan H

Pleural effusion and fibrosis secondary to Sansert administration.

The Annals of thoracic surgery. 1973;15(3):295-8